2cureX - Subscription period for the warrants starts 26/4-21
-
The exercise price for the warrants of series TO1 in 2cureX AB has been determined to SEK 13.22 and the subscription period starts April 26, 2021
April 23, 2021
NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN THE UNITED STATES, AUSTRALIA, CANADA, NEW ZEALAND, HONG KONG, JAPAN, SINGAPORE, SOUTH AFRICA, SOUTH KOREA OR ANY OTHER JURISDICTION WHERE SUCH RELEASE, PUBLICATION OR DISTRIBUTION WOULD BE UNLAWFUL OR WOULD REQUIRE REGISTRATION OR ANY OTHER MEASURES. PLEASE REFER TO IMPORTANT INFORMATION AT THE END OF THE PRESS RELEASE.
2cureX AB ("2cureX" or the "Company") completed a directed issue of units during the third quarter of 2020. One (1) unit consisted of two (2) newly issued shares and one (1) warrant of series TO1. Each warrant gives the owner the right to subscribe for one (1) new share in the Company. The exercise price for the warrants of series TO1 is to be determined to 70 percent of the volume-weighted average price in the Company's share on Nasdaq First North Growth Market during the measurement period, from April 9, 2021, to April 22, 2021, however not lower than the quota value of the Company's share and not higher than SEK 28.88. During the measurement period, the volume-weighted average price in the Company's share was approximately SEK 18.89, therefore, the exercise price for the warrants of series TO1 is set to SEK 13.22. The subscription period for warrants of series TO1 runs from April 26, 2021 up to and including May 7, 2021.
If all the warrants of series TO1 are exercised, the Company will receive approximately SEK 32.46 million before issuing costs. For the warrants to not expire without value, it is required that the holder actively subscribes for new shares no later than May 7, 2021 or sell the warrants no later than May 5, 2021. Please observe that certain nominees might close their application earlier than May 7, 2021.
An independent document with complete terms and conditions for the warrants and documents pursuant to chapter 14 section 32 of the Swedish Companies Act will be available at the Company's website, www.2curex.com.
Summarized terms for the warrants of series TO1:
Subscription period: April 26 - May 7, 2021.Issue size: 2,455,000 warrants of series TO1, which entitles to subscription of 2,455,000 shares. If all the warrants are exercised, The Company will receive approximately SEK 32.46 million before issuing costs.
Exercise price: SEK 13.22 per share.
Last day for trading warrants of series TO1: May 5, 2021.
Dilution etc.: If all warrants are exercised the share capital will increase with SEK 245,500, from SEK 1,484,600, to SEK 1,730,100. If all warrants are exercised the number of shares will increase with 2,455,000 shares, from 14,846,000 shares, to 17,301,000 shares. The dilution at exercise of all warrants amounts to 14.19 percent of the number of shares and 14.19 percent of the number of votes.
Note that the warrants that are not exercised at the latest May 7, 2021, or sold at the latest May 5, 2021, will expire without value. For the warrants not to lose their value, the holder must actively subscribe for new shares or sell the warrants.
How warrants are exercised:
Nominee-registered warrants (Custody account)
Subscription and payment by exercise of warrants shall be made in accordance with instructions from each nominee. Please contact your nominee for additional information.Direct-registered warrants (Securities account)
No accounts for issuing nor any instructions regarding payments will be sent out. Subscriptions will be made through simultaneous payment in accordance with the instructions on the application form.The warrants will then be replaced by interim shares awaiting registration at the Swedish Companies Registration Office.
The application form including instructions for payment will be available at 2cureX's website, www.2curex.com and on Mangold Fondkommission AB's website, www.mangold.se.
Advisers
Mangold Fondkommission AB is financial adviser and Eversheds Sutherland Advokatbyrå AB is legal advisor to 2cureX regarding the warrants.For questions regarding the warrants, please contact:
Mangold Fondkommission AB
Tel: +46 8 5030 1595
E-mail: [email protected]For more information regarding 2cureX, please contact:
Fernando Andreu
Chief Executive Officer
Tel: +45 22 79 53 99
E-mail: [email protected]Certified Adviser
Redeye AB
Phone: +46 8 121 576 90
Mail: [email protected] -
Investorpræsentationer:
May 5, 2021
Redeye Investor theme: Medtech & Diagnostics, Stockholm
Læs mere:
https://www.redeye.se/events/802431/theme-medtech-diagnostics-may-5th
May 26, 2021
Life Science Investor Conference, Copenhagen
Læs mere:
https://lifescience.ugebrev.dk/event-directory/
June 2, 2021
Redeye Growth Day 2021, Stockholm
Læs mere:
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind